Health Care • Biotechnology: Pharmaceutical Preparations
$60.49 ▲ +0.28
(+0.47%)
MKT CAP: $8.54B • VOL: 1.28M
52W L $37 52W H $95
ARWR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $829.4M | $3.6M | $240.7M |
| YoY Revenue Growth % | +23258.2% | -98.5% | — |
| Gross Profit | $365.0M | $1.6M | $105.9M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $98.3M | -$601.1M | -$205.0M |
| Operating Margin % | 11.9% | -16927.1% | -85.2% |
| Net Income (GAAP) | -$1.6M | -$599.5M | -$205.3M |
| EBITDA (Normalized) | $116.5M | -$487.9M | -$196.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $179.6M | -$462.9M | -$153.9M |
| Capital Expenditures (CapEx) | $22.7M | $141.5M | $10.8M |
| Free Cash Flow (FCF) | $156.9M | -$604.3M | -$164.7M |
| FCF Margin % | 18.9% | -17018.3% | -68.4% |
| Return on Invested Capital (ROIC %) | 10.1% | -45.0% | -5.7% |
| Cash & Short-Term Equivalents | $176.5M | $111.5M | $516.9M |
| Total Debt (Short + Long Term) | $375.4M | $237.2M | $1.10B |
| Total Stockholders' Equity | $568.4M | $52.6M | $2.26B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARWR.